- Home
- CYN vs MYNZ Comparison
CYN vs MYNZ Comparison
Compare CYN & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYN
- MYNZ
- Stock Information
- Founded
- CYN 2013
- MYNZ 2021
- Country
- CYN United States
- MYNZ Germany
- Employees
- CYN 81
- MYNZ N/A
- Industry
- CYN EDP Services
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- CYN Technology
- MYNZ Health Care
- Exchange
- CYN Nasdaq
- MYNZ Nasdaq
- Market Cap
- CYN 2.2M
- MYNZ 11.9M
- IPO Year
- CYN 2021
- MYNZ 2021
- Fundamental
- Price
- CYN $0.08
- MYNZ $7.25
- Analyst Decision
- CYN
- MYNZ Hold
- Analyst Count
- CYN 0
- MYNZ 2
- Target Price
- CYN N/A
- MYNZ N/A
- AVG Volume (30 Days)
- CYN 14.2M
- MYNZ 167.6K
- Earning Date
- CYN 03-05-2025
- MYNZ 10-21-2024
- Dividend Yield
- CYN N/A
- MYNZ N/A
- EPS Growth
- CYN N/A
- MYNZ N/A
- EPS
- CYN N/A
- MYNZ N/A
- Revenue
- CYN $102,118.00
- MYNZ $917,203.00
- Revenue This Year
- CYN $18.11
- MYNZ $21.95
- Revenue Next Year
- CYN $198.58
- MYNZ $30.77
- P/E Ratio
- CYN N/A
- MYNZ N/A
- Revenue Growth
- CYN N/A
- MYNZ 16.23
- 52 Week Low
- CYN $0.07
- MYNZ $0.18
- 52 Week High
- CYN $25.90
- MYNZ $7.95
- Technical
- Relative Strength Index (RSI)
- CYN 22.03
- MYNZ 73.68
- Support Level
- CYN $0.50
- MYNZ $5.50
- Resistance Level
- CYN $0.63
- MYNZ $5.74
- Average True Range (ATR)
- CYN 0.07
- MYNZ 0.87
- MACD
- CYN 0.09
- MYNZ 0.26
- Stochastic Oscillator
- CYN 0.07
- MYNZ 87.38
About CYN Cyngn Inc.
Cyngn Inc is an industrial autonomous vehicle technology company. Its flagship innovation is DriveMod, an autonomous driving solution that can be flexibly deployed on multiple vehicle types manufactured by Original Equipment Manufacturers in various environments.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples.